Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.49 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3488943 | 0.98 | ALDH1A1 (0.50) | LMNAALDH1A1CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL3276016 | 0.97 | ALDH1A1 (0.49) | LMNAALDH1A1CA12CA1CA2 | |
| SCHEMBL28087330 | 0.85 | ALDH1A1 (0.50) | LMNAALDH1A1CA12CA1CA2 | |
| SCHEMBL3577048 | 0.85 | ALDH1A1 (0.49) | LMNAALDH1A1CA12CA1CA2 | |
| SCHEMBL30069255 | 0.84 | NPC1 (0.48) | LMNAALDH1A1MAPTRAB9AHTT | |
| SCHEMBL9912720 | 0.84 | NPC1 (0.48) | LMNAALDH1A1MAPTRAB9AHTT | |
| SCHEMBL27795167 | 0.82 | SMN1; SMN2 (0.52) | LMNAALDH1A1MAPTRAB9ARECQL | |
| SCHEMBL11021555 | 0.82 | ALDH1A1 (0.48) | LMNAALDH1A1MAPTRAB9AHTT | |
| Hydrochloric Acid SCHEMBL3601018 | 0.81 | ALDH1A1 (0.55) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL19172441 | 0.81 | NPC1 (0.50) | LMNAALDH1A1MAPTRAB9AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110225912-B | GSK-3 inhibitors | 百时美施贵宝公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-114315706-A | Synthetic method of 3, 4-diaminopyridine | 河北一品生物医药有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-7790740-B2 | Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflammation | PFIZER INC (US) | 2010-09-07 | — | — | US | disclosed |
| US-7772226-B2 | Condensed imidazole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| EP-1747210-B1 | 3- OR 4-MONOSUBSTITUTED PHENOL AND THIOPHENOL DERIVATIVES USEFUL AS H3 LIGANDS | WARNER LAMBERT CO (US) | 2010-06-30 | — | — | EP | disclosed |
| US-7579471-B2 | Tropane derivatives useful in therapy | PFIZER, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090209578-A1 | CHEMICAL COMPOUNDS | PFIZER INC | 2009-08-20 | — | — | US | disclosed |
| US-7524847-B2 | Fused 1,3-dihydro-imidazole ring compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-04-28 | — | — | US | disclosed |
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-01-15 | — | — | US | disclosed |
| US-7456164-B2 | Useful for treatment of H3-related diseases such as neurologic disorders, or inflammatory, respiratory and allergic diseases, disorders and conditions; for example, 4-[4-(1-isopropylpiperidin-4-yloxy)phenyl]tetrahydropyran-4-carbonitrile; well absorbed from gastrointestinal tract, metabolically stable | PFIZER, INC (US) | 2008-11-25 | — | — | US | disclosed |
| WO-2004064778-A2 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO. INC. (US) | 2004-08-05 | — | — | WO | disclosed |
| US-20040116328-A1 | Condensed imidazole derivatives | EISAI CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
| US-20040014742-A1 | Antiinflammatory agents; viricides | PFIZER INC. | 2004-01-22 | — | — | US | disclosed |
| WO-2003084954-A1 | TROPANE DERIVATIVES AS CCR5 MODULATORS | PFIZER LIMITED (GB) | 2003-10-16 | — | — | WO | disclosed |
| EP-0399653-B1 | Anticonvulsant triazolo[4,5-c]pyridine derivatives | WELLCOME FOUND (GB) | 1994-10-19 | — | — | EP | disclosed |
| EP-0431799-A2 | Use of nucleoside derivatives as cytotoxic agents | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-06-12 | — | — | EP | disclosed |
| EP-0399653-A1 | Anticonvulsant triazolo[4,5-c]pyridine derivatives | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-11-28 | — | — | EP | disclosed |
| EP-0149537-B1 | PROCESS FOR THE SYNTHESIS OF AMINONITROPYRIDINES | ELI LILLY AND COMPANY (US) | 1988-07-13 | — | — | EP | disclosed |
| US-4552967-A | Process for the synthesis of intermediates in the preparation of diaminopyridines | ELI LILLY AND COMPANY (US) | 1985-11-12 | — | — | US | disclosed |
| EP-0149537-A2 | Process for the synthesis of aminonitropyridines | ELI LILLY AND COMPANY (US) | 1985-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014742-A1 | Antiinflammatory agents; viricides | CCR5, CXCR1, CCR1 | CA2 2585/4885GAA 3554/4885LMNA 4096/4885 |
| US-20090209578-A1 | CHEMICAL COMPOUNDS | CCR5, CXCR3, CXCR1 | CA2 2733/4885GAA 4783/4885LMNA 4759/4885 |
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | DPP4, HDAC1, DPP7 | CA2 76/4885GAA 3065/4885LMNA 3909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.